摘要
目的探究大黄灵仙胶囊对肝内胆管细胞TGF-β1、SMAD2、BMP2表达水平的影响,分析其缓解细胞炎症,防治胆石症的相关作用机制。方法制备大黄灵仙胶囊的含药血清,采用脂多糖(LPS)诱导构建肝内胆管细胞炎症状态模型并用大黄灵仙胶囊含药血清进行干预;实验分为对照组、模型组和大黄灵仙组;72 h后ELISA检测IL-18炎症因子的表达水平;Western blot检测胆管细胞TGF-β1、SMAD2、BMP2蛋白的表达,RT-PCR检测胆管细胞TGF-β1、SMAD2、BMP2 mRNA的表达水平。结果与对照组比较,模型组IL-18炎症因子含量显著增加,TGF-β1、SMAD2、BMP2蛋白和mRNA表达水平明显上升,差异均具有统计学意义(P<0.01或P<0.05)。与模型组比较,大黄灵仙组IL-18炎症因子表达水平明显降低,TGF-β1、SMAD2、BMP2蛋白和mRNA表达显著下降,差异均具有统计学意义(P<0.01或P<0.05)。结论大黄灵仙胶囊能够显著降低TGF-β1、SMAD2、BMP2的表达水平,延缓胆管细胞的炎症反应进程,阻止纤维化,从而起到防治胆石症的作用。
Objective To explore the effects of DHLX on the expression levels of TGF-β1, SMAD2 and BMP2 in intrahepatic bile duct cells, and to analyze the mechanism of its action in relieving cellular inflammation and preventing cholelithiasis.Methods The drug serum of DHLX was prepared, and the inflammation state model of intrahepatic bile duct cells was induced by lipopolysaccharide(LPS), and the drug serum of DHLX was used to intervene. The experiment was divided into control group, model group and DHLX group. The expression level of IL-18 inflammatory factor was detected by ELISA after 72 h. Western blot was used to detect the expression of TGF-β1, SMAD2 and BMP2 proteins in bile duct cells, and RT-PCR was used to detect the mRNA expression levels of TGF-β1, SMAD2 and BMP2 in bile duct cells.Results Compared with the control group, the content of IL-18 inflammatory factor and the expression levels of TGF-β1, SMAD2 and BMP2 protein and mRNA in the model group were significantly increased, with statistical significance(P<0.01 or P<0.05). Compared with the model group, the expression level of IL-18 inflammatory factor and the protein and mRNA expressions of TGF-β1, SMAD2 and BMP2 in DHLX group were significantly decreased, and the differences were statistically significant(P<0.01 or P<0.05).Conclusion DHLX can significantly reduce the expression levels of TGF-β1, SMAD2 and BMP2, delay the inflammatory reaction process of bile duct cells, prevent fibrosis, and thus play a role in the prevention and treatment of cholelithiasis.
作者
居燕飞
王清坚
蒙健林
劳永彩
陈雅璐
JU Yan-fei;WANC Qing-jan;MENG Jian-lin;LAO Yong-cai;CHEN Ya-lu(Guangxi University of Chinese Medicine,Nanning Guangxi 530200,China;First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning Guangxi 530023,China)
出处
《时珍国医国药》
CAS
CSCD
北大核心
2024年第3期528-531,共4页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金地区基金项目(82060867)
广西壮族自治区研究生教育创新计划项目(YCSW2022350)。
